RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:2 weeks: It’s all it took for Merck to get AAManagement report of 29th November, does not seem to indicate any extension to the commercial revenue projections that they made earlier. I stil expect their previous projection date of 1st quarter of 2023 to be the estimate for commercial revenue.
The report of 29th Nov, has more clarity, meaning that they have provided actual Number of patientsand the results at different dates. Especially this
" The Company will compile a clinical data report for submission to the FDA in support of the grant of a BTD approval after completion of the 450 assessments for 25 patients, expected in 4Q2022, "
BTD is very likely to be awarded, and possibly AA as well by the end of 1st quarter 2023. After that I expect commercial production starts. Once you start treating patients based on AA status, commercial revenue has to follow. We may still need to raise more money since commercial production requires way more money. Atleast, by then we will have a much higher stock price and hopefully the next PP will be at $1 or more instead of the last cheap diluation at $0.25 + a free warrant.